Edwards Lifesciences (EW) Given Daily Coverage Optimism Score of 0.20
Press coverage about Edwards Lifesciences (NYSE:EW) has been trending somewhat positive on Monday, Accern Sentiment reports. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Edwards Lifesciences earned a news impact score of 0.20 on Accern’s scale. Accern also gave news stories about the medical research company an impact score of 47.2641846066809 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of Edwards Lifesciences (NYSE:EW) traded down $0.81 during trading on Monday, reaching $112.49. 917,100 shares of the company were exchanged, compared to its average volume of 1,636,604. The company has a market capitalization of $23,630.00, a P/E ratio of 32.70, a price-to-earnings-growth ratio of 2.03 and a beta of 0.51. Edwards Lifesciences has a 12 month low of $86.55 and a 12 month high of $121.45. The company has a current ratio of 3.49, a quick ratio of 2.76 and a debt-to-equity ratio of 0.33.
Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, October 24th. The medical research company reported $0.84 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.86 by ($0.02). The company had revenue of $821.50 million for the quarter, compared to the consensus estimate of $833.85 million. Edwards Lifesciences had a net margin of 22.47% and a return on equity of 27.22%. The firm’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same quarter last year, the company earned $0.68 EPS. equities research analysts predict that Edwards Lifesciences will post 3.76 earnings per share for the current fiscal year.
Edwards Lifesciences declared that its Board of Directors has authorized a share buyback plan on Thursday, December 7th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to buy shares of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s leadership believes its shares are undervalued.
EW has been the topic of a number of recent analyst reports. William Blair reiterated an “outperform” rating on shares of Edwards Lifesciences in a report on Monday, August 28th. BMO Capital Markets reiterated a “buy” rating and set a $132.00 price target on shares of Edwards Lifesciences in a report on Friday, September 1st. Royal Bank of Canada reiterated a “buy” rating and set a $130.00 price target on shares of Edwards Lifesciences in a report on Friday, September 1st. Zacks Investment Research cut shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 26th. Finally, Barclays reiterated an “equal weight” rating and set a $120.00 price target on shares of Edwards Lifesciences in a report on Saturday, September 30th. Six equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $126.43.
In other Edwards Lifesciences news, VP Larry L. Wood sold 18,960 shares of the stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $108.54, for a total value of $2,057,918.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Michael A. Mussallem sold 32,900 shares of the stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $100.93, for a total transaction of $3,320,597.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 172,380 shares of company stock worth $18,653,221. 2.13% of the stock is owned by insiders.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with Analyst Ratings Network's FREE daily email newsletter.